Transcriptome Analysis of the Interferon-Signature Defining the Autoimmune Process of Sjögren's Syndrome

Scandinavian Journal of Immunology

Volumn 76, Issue 3, 2012, Pages 237-245

  Peck, A B ^a,b   Nguyen, C Q ^b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

^c University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; TRANSCRIPTOME;

EXOCRINE GLAND; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE INTERACTION; GENETIC TRANSCRIPTION; HUMAN; LACRIMAL GLAND; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME;

ANIMALS; AUTOIMMUNITY; GENE EXPRESSION PROFILING; HUMANS; INTERFERONS; MICE; SJOGREN'S SYNDROME; TRANSCRIPTOME;

EID: 84865355994     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02749.x     Document Type: Review

References (58)

1. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand J Rheumatol 2000;29:341-8.
2. Hansen A, Lipsky PE, Dorner T. New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers. Curr Opin Rheumatol 2003;15:563-70.
3. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31.
4. Manthorpe R, Bredberg A, Henriksson G, Larsson A. Progress and regression within primary Sjogren's syndrome. Scand J Rheumatol 2006;35:1-6.
5. Fox PC, Bowman SJ, Segal B et al. Oral involvement in primary Sjogren syndrome. J Am Dent Assoc 2008;139:1592-601.
6. Delalande S, de Seze J, Fauchais AL et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83:280-91.
7. Malinow KL, Molina R, Gordon B, Selnes OA, Provost TT, Alexander EL. Neuropsychiatric dysfunction in primary Sjogren's syndrome. Ann Intern Med 1985;103:344-50.
8. Belin C, Moroni C, Caillat-Vigneron N et al. Central nervous system involvement in Sjogren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. Ann Med Interne (Paris) 1999;150:598-604.
9. Valtysdottir ST, Gudbjornsson B, Lindqvist U, Hallgren R, Hetta J. Anxiety and depression in patients with primary Sjogren's syndrome. J Rheumatol 2000;27:165-9.
10. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
11. Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep 2003;5:317-23.
12. Ansell P, Simpson J, Lightfoot T et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter? Int J Cancer 2011;129:460-6.
13. Bave U, Nordmark G, Lovgren T et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95.
14. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33.
15. Emamian ES, Leon JM, Lessard CJ et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009;10:285-96.
16. Zheng L, Zhang Z, Yu C, Tu L, Zhong L, Yang C. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e12-8.
17. Vakaloglou KM, Mavragani CP. Activation of the type I interferon pathway in primary Sjogren's syndrome: an update. Curr Opin Rheumatol 2011;23:459-64.
18. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010;35:225-31.
19. Cha S, Brayer J, Gao J et al. A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 2004;60:552-65.
20. Cha S, van Blockland SC, Versnel MA et al. Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet 2001;18:143-60.
21. Macmicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 2012;12:367-82.
22. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res 2011;31:5-11.
23. Killedar SY, Eckenrode SE, McIndoe RA et al. Early pathogenic events associated with Sjogren's syndrome (SjS)-like disease of the nod mouse using microarray analysis. Lab Invest 2006;86:1243-60.
24. Kawakami A, Nakashima K, Tamai M et al. Toll-like receptor in salivary glands from patients with Sjogren's syndrome: functional analysis by human salivary gland cell line. J Rheumatol 2007;34:1019-26.
25. Spachidou MP, Bourazopoulou E, Maratheftis CI et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol 2007;147:497-503.
26. Peck AB, Nguyen CQ, Sharma A, McIndoe RA, She JX. The interferon-signature of Sjögren's syndrome: what does it say about the etiopathology of autoimmunity. J Clin Rheum & Musculoskeletal Med 2011;1:1-17.
27. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44.
28. Gottenberg JE, Cagnard N, Lucchesi C et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Nat Acad Sci USA 2006;103:2770-5.
29. Perez P, Anaya JM, Aguilera S et al. Gene expression and chromosomal location for susceptibility to Sjogren's syndrome. J Autoimmun 2009;33:99-108.
30. Kimoto O, Sawada J, Shimoyama K et al. Activation of the interferon pathway in peripheral blood of patients with Sjogren's syndrome. J Rheumatol 2011;38:310-6.
31. Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A, Chiocchia G. Gene expression profile in the salivary glands of primary Sjogren's syndrome patients before and after treatment with rituximab. Arthritis Rheum 2010;62:2262-71.
32. Wakamatsu E, Nakamura Y, Matsumoto I et al. DNA microarray analysis of labial salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2007;66:844-5.
33. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010;19:1012-9.
34. Raterman HG, Vosslamber S, de Ridder S et al. Interferon type I signature may predict non response upon rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R95.
35. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background. Arthritis Rheum 2002;46:1390-8.
36. Toniato E, Chen XP, Losman J, Flati V, Donahue L, Rothman P. TRIM8/GERP RING finger protein interacts with SOCS-1. J Biol Chem 2002;277:37315-22.
37. Wang H, Lee CH, Qi C et al. IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood 2008;112:4028-38.
38. Ohlsson M, Szodoray P, Loro LL, Johannessen AC, Jonsson R. CD40, CD154, Bax and Bcl-2 expression in Sjogren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand J Immunol 2002;56:561-71.
39. Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002;127:386-92.
40. Yang K, Shi HX, Liu XY et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 2009;182:3782-92.
41. Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006;2:262-9.
42. Nordmark G, Eloranta ML, Ronnblom L. Primary Sjogren's syndrome and the type I interferon system. Curr Pharm Biotechnol 2012;Jan 2.
43. Nguyen CQ, Kim H, Cornelius JG, Peck AB. Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. J Immunol 2007;179:2318-29.
44. Nguyen C, Cornelius J, Singson E, Killedar S, Cha S, Peck AB. Role of complement and B lymphocytes in Sjogren's syndrome-like autoimmune exocrinopathy of NOD.B10-H2b mice. Mol Immunol 2006;43:1332-9.
45. Nguyen CQ, Sharma A, Lee BH, She JX, McIndoe RA, Peck AB. Differential gene expression in the salivary gland during development and onset of xerostomia in Sjogren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Arthritis Res Ther 2009;11:R56.
46. Staeheli P, Sutcliffe JG. Identification of a second interferon-regulated murine Mx gene. Mol Cell Biol 1988;8:4524-8.
47. Rogozin IB, Aravind L, Koonin EV. Differential action of natural selection on the N and C-terminal domains of 2′-5′ oligoadenylate synthetases and the potential nuclease function of the C-terminal domain. J Mol Biol 2003;326:1449-61.
48. Choubey D, Duan X, Dickerson E et al. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res 2010;30:371-80.
49. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2:965-75.
50. Wu AJ, Chen ZJ, Tsokos M, O'Connell BC, Ambudkar IS, Baum BJ. Interferon-gamma induced cell death in a cultured human salivary gland cell line. J Cell Physiol 1996;167:297-304.
51. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-36.
52. Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 2010;22:740-6.
53. Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol 2009;175:1136-47.
54. Jefferies C, Wynne C, Higgs R. Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease? Nat Rev Immunol 2011;11:617-25.
55. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011;23:46-56.
56. Kawai T, Akira S. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med 2011;3:513-27.
57. Dimitriou ID, Clemenza L, Scotter AJ, Chen G, Guerra FM, Rottapel R. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol Rev 2008;224:265-83.
58. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol 2010;6:529-37.